Open to all ISPOR Members and Non-members

Presented by:

  • Catherine M. Lockhart, PharmD, PhD
  • Jacqueline Vanderpuye-Orgle, PhD, MSc
  • Jeffrey R Curtis, MD MS MPH
  • Molly Leber, PharmD, BCPS, FASHP
  • Anna Hyde, MA

Monday, September 28, 2020
12:00PM EDT | 4:00PM GMT | 6:00PM CEST

Click here for time zone conversion

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.  By way of societal benefits, biosimilars have been widely expected to improve patient access to life-saving biologics while reflecting in substantial cost savings.  A RAND report estimates US cost savings of over $50 billion in 10 years.  However, there is wide variability in the estimates as to how biosimilars may benefit various stakeholders.  It is not always clear how these are measured, whether they are meaningful from a patient perspective, and how they can be harnessed to guide access decision making.  Careful consideration of the societal benefits of biosimilars from a multi-stakeholder perspective may provide valuable lessons for fully realizing their potential. 

Dr. Vanderpuye-Orgle will review how the benefits of biosimilars have been measured using case studies from the US and select markets and how this evidence may be used to shape access decisions and foster market sustainability.  Dr. Curtis will discuss a case study on biosimilar infliximab use based on data from the US Medicare program and how trade-offs between savings due to lower prices and increased costs due to dose escalations may affect access decisions.  Ms. Leber will discuss the considerations for payer decision-making on biosimilars access, as well as the challenges and potential solutions for fully realizing the promise of biosimilars.  Ms. Hyde will present specific actions that patient groups such as the Arthritis Foundation are engaged in to help harness the potential benefits of biosimilars for improved access to treatment options.  Dr. Lockhart will chair the forum and moderate the panel discussion.

After attending this webinar, participants will be able to:

  • Provide a consensus on the potential benefits of biosimilars to respective stakeholders in the healthcare ecosystem
  • Describe how these potential benefits of biosimilars are measured from the societal perspective
  • Describe what measure can be put in place to fully realize the potential of biosimilars to improve patient access and provide cost savings


Catherine M. Lockhart, PharmD, PhD
Executive Director
Biologics and Biosimilars Collective Intelligence Consortium
Alexandria, VA, USA


Jacqueline Vanderpuye-Orgle, PhD, MSc
Chair-Elect ISPOR Biosimilars Special Interest Group
Vice President and Advanced Analytics Lead, RWE and HEOR
Parexel International
Los Angeles, CA, USA

Dr. Jeffrey R Curtis, MD, MS, MPH
Marguerite Jones Harbert – Gene Ball Endowed Professor of Medicine
University of Alabama at Birmingham
Birmingham, AL, USA

Molly Leber, PharmD, BCPS, FASHP
Associate Director
Drug Use Policy and Formulary Management
Yale New Haven Health System
New Haven, CT, USA

Anna Hyde, MA
Vice President of Advocacy and Access
Arthritis Foundation
Washington, DC, USA

Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 weeks after the scheduled Webinar.

Reservations are on a first-come, first-served basis for all ISPOR members.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now